Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024PRNewsWire • 02/20/24
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchSeeking Alpha • 01/10/24
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerPRNewsWire • 01/08/24
Gilead Sciences and Compugen strike commercialization deal for immunotherapy programProactive Investors • 12/20/23
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerPRNewsWire • 12/19/23
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 BiologyPRNewsWire • 12/19/23
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy ProgramBusiness Wire • 12/19/23
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to ImmunotherapyPRNewsWire • 11/06/23
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating CancerPRNewsWire • 10/31/23